Accepted Article This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/bjd.16334 This article is protected by copyright. All rights reserved. DR CAROLINE MAHON (Orcid ID : 0000-0002-6399-0086) Article type : Research Letter Oral propranolol for infantile haemangioma may be associated with transient gross motor delay C. Mahon 1,2* , G. Heron 3,4 , D. Perkins 3 , A. Drage 1 , O. Wargon 3,4 1. Bristol Royal Infirmary - Dermatology Bristol BS2 8HW United Kingdom. 2. Great Ormond Street Hospital for Children NHS Trust Dermatology, London WC1N 3JH United Kingdom. 3. Sydney Children's Hospital Randwick - Paediatric Dermatology, Randwick, New South Wales Australia 4. University of New South Wales - Randwick Campus Randwick, New South Wales Australia Corresponding author mail id : caroline_mahon@hotmail.com Oral propranolol, first-line therapy for infantile haemangioma (IH) threatening functional impairment or cosmetic disfigurement, readily crosses the blood-brain barrier. Subsequently therefore, there are concerns about potential effects on infant development. 1 Phillips et al. followed 200 children prescribed propranolol, observing sedative effects during treatment